Andreas Argyrides
Stock Analyst at Oppenheimer
(4.48)
# 269
Out of 4,940 analysts
104
Total ratings
52.75%
Success rate
21.19%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andreas Argyrides
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KALA KALA BIO | Assumes: Outperform | $15 | $7.20 | +108.33% | 1 | Jun 2, 2025 | |
| HRMY Harmony Biosciences Holdings | Assumes: Outperform | $61 | $34.80 | +75.29% | 1 | Jun 2, 2025 | |
| AQST Aquestive Therapeutics | Assumes: Outperform | $15 → $7 | $3.86 | +81.35% | 5 | Jun 2, 2025 | |
| ABEO Abeona Therapeutics | Assumes: Outperform | $19 | $6.28 | +202.55% | 1 | Jun 2, 2025 | |
| DYN Dyne Therapeutics | Assumes: Outperform | $60 → $34 | $11.24 | +202.63% | 1 | Jun 2, 2025 | |
| IFRX InflaRx | Maintains: Outperform | $6 → $3 | $0.82 | +264.52% | 2 | May 29, 2025 | |
| LQDA Liquidia | Downgrades: Underperform | $13 | $21.20 | -38.68% | 7 | May 19, 2025 | |
| RANI Rani Therapeutics Holdings | Maintains: Outperform | $14 → $4 | $0.50 | +700.00% | 5 | May 16, 2025 | |
| KRRO Korro Bio | Maintains: Outperform | $155 → $90 | $15.05 | +498.01% | 1 | May 13, 2025 | |
| PRQR ProQR Therapeutics | Maintains: Outperform | $15 → $9 | $1.89 | +376.19% | 1 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $47 → $15 | $13.36 | +12.28% | 8 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $181 | $195.93 | -7.62% | 9 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $11.79 | +196.86% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $26 | $3.78 | +587.83% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $104 | $53.15 | +95.67% | 14 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $0.40 | +1,140.69% | 1 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $9 | $1.74 | +418.73% | 8 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $19 | $16.38 | +16.00% | 9 | Mar 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $17.97 | +61.38% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $21 | $7.46 | +181.50% | 4 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $224 | $17.94 | +1,148.61% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $25.20 | +126.19% | 2 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $7 | $0.85 | +724.50% | 3 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $3.42 | +192.40% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $10 | $0.44 | +2,170.66% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $70 | $56.80 | +23.24% | 6 | Aug 1, 2023 |
KALA BIO
Jun 2, 2025
Assumes: Outperform
Price Target: $15
Current: $7.20
Upside: +108.33%
Harmony Biosciences Holdings
Jun 2, 2025
Assumes: Outperform
Price Target: $61
Current: $34.80
Upside: +75.29%
Aquestive Therapeutics
Jun 2, 2025
Assumes: Outperform
Price Target: $15 → $7
Current: $3.86
Upside: +81.35%
Abeona Therapeutics
Jun 2, 2025
Assumes: Outperform
Price Target: $19
Current: $6.28
Upside: +202.55%
Dyne Therapeutics
Jun 2, 2025
Assumes: Outperform
Price Target: $60 → $34
Current: $11.24
Upside: +202.63%
InflaRx
May 29, 2025
Maintains: Outperform
Price Target: $6 → $3
Current: $0.82
Upside: +264.52%
Liquidia
May 19, 2025
Downgrades: Underperform
Price Target: $13
Current: $21.20
Upside: -38.68%
Rani Therapeutics Holdings
May 16, 2025
Maintains: Outperform
Price Target: $14 → $4
Current: $0.50
Upside: +700.00%
Korro Bio
May 13, 2025
Maintains: Outperform
Price Target: $155 → $90
Current: $15.05
Upside: +498.01%
ProQR Therapeutics
May 13, 2025
Maintains: Outperform
Price Target: $15 → $9
Current: $1.89
Upside: +376.19%
Jan 17, 2025
Downgrades: Neutral
Price Target: $47 → $15
Current: $13.36
Upside: +12.28%
Nov 15, 2024
Reiterates: Outperform
Price Target: $181
Current: $195.93
Upside: -7.62%
Oct 16, 2024
Initiates: Outperform
Price Target: $35
Current: $11.79
Upside: +196.86%
Oct 16, 2024
Initiates: Outperform
Price Target: $26
Current: $3.78
Upside: +587.83%
Jun 25, 2024
Initiates: Outperform
Price Target: $104
Current: $53.15
Upside: +95.67%
Jun 25, 2024
Initiates: Outperform
Price Target: $5
Current: $0.40
Upside: +1,140.69%
Jun 25, 2024
Initiates: Outperform
Price Target: $9
Current: $1.74
Upside: +418.73%
Mar 11, 2024
Reiterates: Outperform
Price Target: $19
Current: $16.38
Upside: +16.00%
Mar 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $17.97
Upside: +61.38%
Feb 28, 2024
Reiterates: Neutral
Price Target: $21
Current: $7.46
Upside: +181.50%
Feb 20, 2024
Reiterates: Outperform
Price Target: $224
Current: $17.94
Upside: +1,148.61%
Feb 8, 2024
Reiterates: Outperform
Price Target: $57
Current: $25.20
Upside: +126.19%
Oct 10, 2023
Maintains: Outperform
Price Target: $5 → $7
Current: $0.85
Upside: +724.50%
Oct 10, 2023
Initiates: Outperform
Price Target: $10
Current: $3.42
Upside: +192.40%
Aug 11, 2023
Maintains: Outperform
Price Target: $16 → $10
Current: $0.44
Upside: +2,170.66%
Aug 1, 2023
Maintains: Neutral
Price Target: $73 → $70
Current: $56.80
Upside: +23.24%